Nanobiotix SA (NASDAQ:NBTX) announced new results focused on patients with primary cutaneous melanoma from an ongoing Phase 1 Study.

1100 evaluating JNJ-1900 (NBTXR3) in combination with immune checkpoint inhibitors (pembrolizumab or nivolumab) for advanced cancer patients.

All 21 patients with primary cutaneous melanoma had shown prior resistance to anti-PD-1, and treatment with RT-activated JNJ-1900 (NBTXR3), followed by anti-PD-1, showed a favorable safety profile:

Nanobiotix confirmed injection feasibility at the recommended Phase 2 dose (33%  gross tumor volume or GTV).

In total, 16 patients experienced grade 1, grade 2, or grade 3+ TEAEs related to the overall therapeutic regimen.

Also Read: Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden

Early Signs of Efficacy

A relationship was observed between the depth of local response and systemic tumor regression, suggesting a possible priming or reactivation of the immune response.

In 2023, Nanobiotix announced a license agreement for the global co-development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson (NYSE:JNJ) company.

Price Action: NBTX stock is up 22.03% at $12.45 at the last check on Thursday.

Read Next:

• MediaTek Adopts Taiwan Semiconductor 2nm Breakthrough For Flagship Chip

Image: Shutterstock